上海证券交易所 为促进华夏中证5G通信主题交易型开放式指数证券投资基金（以下简称5GETF，基金代 码:515050）的市场流动性和平稳运行，根据《上海证券交易所基金自律监管规则适用指引第2号——上 市基金做市业务》等相关规定，本所同意国泰海通证券股份有限公司自2026年02月03日起为5GETF提供 主做市服务。 2026年02月02日 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 特此公告。 上证公告（基金）【2026】236号 ...

特此公告。 为促进易方达中证软件服务交易型开放式指数证券投资基金（以下简称软件30，基金代 码:562930）的市场流动性和平稳运行，根据《上海证券交易所基金自律监管规则适用指引第2号——上 市基金做市业务》等相关规定，本所同意国泰海通证券股份有限公司自2026年02月03日起为软件30提供 主做市服务。 上海证券交易所 上证公告（基金）【2026】240号 2026年02月02日 ...

Core Viewpoint - Haier Biomedical (688139.SH) announced a share reduction plan by its shareholder, Qingdao Haichuangrui Equity Investment Fund Center, due to funding needs, intending to reduce up to 0.85% of its total shares, equating to a maximum of 2,690,189 shares [1] Group 1 - Haichuangrui plans to reduce its holdings in Haier Biomedical through centralized bidding, with a reduction period starting 15 trading days after the announcement and lasting for three months [1] - As of the last trading day before the announcement, Haier Biomedical's share price was 33.34 yuan per share, estimating the reduction amount to be approximately 89.69 million yuan [1] - Haichuangrui currently holds 32,103,659 shares of Haier Biomedical, representing 10.14% of the total share capital [1] Group 2 - Haichuangrui has signed a voting rights entrustment agreement with Haier Group, establishing a concerted action relationship [2] - Haier Group, through its controlled entity, Qingdao Haier Biomedical Medical Holdings, holds 100,591,463 shares, accounting for 31.78% of Haier Biomedical's total shares [2] - Another concerted action partner, Qingdao Haichuangzhi Management Consulting Enterprise, holds 8,675,900 shares, representing 2.74% of the total shares [2] Group 3 - Haier Biomedical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 25, 2019, after receiving approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [3] - The company issued a total of 79,267,940 shares at a price of 15.53 yuan per share, raising approximately 1.23 billion yuan, with actual funds received amounting to about 1.16 billion yuan [3] - The funds were verified by Ernst & Young Hua Ming and were received on October 22, 2019, with Guotai Junan Securities serving as the lead underwriter [3]

Core Viewpoint - Shengmei Shanghai (688082.SH) announced a share transfer plan on January 31, 2023, where its controlling shareholder, ACMR, intends to transfer 4,801,648 shares, representing 1.00% of the total share capital, due to personal funding needs [1][2]. Group 1: Share Transfer Details - The transferring party, ACMR, holds 74.49% of Shengmei Shanghai's total shares and is controlled by HUI WANG, who is also the chairman [1]. - The share transfer will not occur through centralized bidding or block trading, and the minimum transfer price will be set at no less than 70% of the average trading price over the previous 20 trading days [2]. - The total amount expected to be raised from the share transfer is approximately 90.66 million yuan, based on the closing price of 188.80 yuan on January 30, 2023 [1]. Group 2: Shareholder Reduction Results - As of November 21, 2025, HUI WANG and other associated parties have reduced their holdings, with HUI WANG selling 199,794 shares (0.04% of total shares) and other executives also reducing their stakes [3]. - The total amount raised from these reductions includes 34,633,920.43 yuan from HUI WANG and 24,786,328.00 yuan from Wang Jian, among others [4]. Group 3: Fundraising History - Shengmei Shanghai went public on November 18, 2021, raising a total of 3.685 billion yuan, with a net amount of 3.481 billion yuan after deducting issuance costs [4]. - The company initially planned to raise 1.8 billion yuan for semiconductor equipment R&D and working capital, but the final net amount exceeded the original plan by 1.681 billion yuan [4]. - The total fundraising amount from two rounds of financing is approximately 8.167 billion yuan [6].

Group 1 - The company, Zhixiang Jintai, forecasts a significant increase in revenue for 2025, estimating between 209.45 million to 250.88 million yuan, representing a year-on-year growth of 595.96% to 733.62% [1] - The company anticipates a reduction in net loss for 2025, projecting a loss of between 480.64 million to 587.45 million yuan, which is a decrease of 20.98 million to 316.64 million yuan compared to the previous year, reflecting a year-on-year reduction of 26.32% to 39.71% [1] - The company's net profit attributable to shareholders from 2021 to 2024 has shown consistent losses, with figures of -322 million, -576 million, -801 million, and -797 million yuan respectively [1] Group 2 - Zhixiang Jintai was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 20, 2023, with an initial public offering of 91.68 million shares at a price of 37.88 yuan per share [2] - The total amount raised from the IPO was 3.47 billion yuan, with a net amount of 3.29 billion yuan after deducting issuance costs, which was 688.60 million yuan less than the originally planned amount [2] - The company intended to raise 3.98 billion yuan for projects related to antibody industrialization and research, but the actual fundraising fell short of this target [2]

Core Viewpoint - ACM Research, Inc. plans to transfer 4,801,648 shares of Shengmei Semiconductor Equipment (Shanghai) Co., Ltd., representing 1.00% of the total share capital, through a pre-IPO shareholder inquiry transfer to meet its funding needs [3][8]. Group 1: Share Transfer Details - The total number of shares to be transferred is 4,801,648, which accounts for 1.00% of Shengmei Shanghai's total share capital as of January 30, 2026 [3][4]. - The transfer will not occur through centralized bidding or block trading and is not classified as a secondary market reduction [3]. - The shares acquired through this inquiry transfer cannot be transferred within six months after acquisition [3]. Group 2: Seller Information - The seller, ACMR, is the controlling shareholder of Shengmei Shanghai and is associated with HUI WANG, who is the chairman and actual controller of the company [5]. - ACMR has confirmed that the shares are free from any restrictions or prohibitions on transfer and comply with relevant regulations [5][6]. Group 3: Transfer Pricing and Conditions - The minimum transfer price will not be lower than 70% of the average trading price over the 20 trading days prior to January 30, 2026 [8]. - If the total number of valid subscriptions exceeds the number of shares available, the transfer price will be determined based on price priority, quantity priority, and time priority [9]. Group 4: Investor Eligibility - Eligible investors for the inquiry transfer include institutional investors with appropriate pricing capabilities and risk tolerance, such as securities companies, fund management companies, and qualified foreign institutional investors [10]. Group 5: Company Risk and Control - Shengmei Shanghai does not face any operational risks that require disclosure under the relevant stock exchange rules [11]. - The inquiry transfer is not expected to result in a change of control for Shengmei Shanghai [11].

Core Viewpoint - The company has announced the opening and modification of certain special accounts for raised funds and the re-signing of a four-party supervision agreement, which aims to optimize fund management and improve efficiency without changing the intended use of the funds [1][9]. Fundraising Basic Information - The company was approved by the China Securities Regulatory Commission to publicly issue convertible bonds totaling RMB 1,200,000,000, with a net amount of RMB 1,193,773,584.91 after deducting issuance costs [1][2]. Special Account Opening and Changes - The company plans to close the special account at China Construction Bank and transfer all remaining funds to a new special account at Industrial and Commercial Bank of China, ensuring that the balance will be fully transferred [2][3]. - The new special account will be used for the storage and management of raised funds, with any interest or income generated during the storage period also deposited into this account [3][4]. Four-Party Supervision Agreement - The new supervision agreement involves the company, its subsidiary, the Industrial and Commercial Bank of China, and the sponsor, Guotai Junan Securities, ensuring compliance with relevant regulations [4][12]. - The agreement stipulates that funds cannot be used without prior approval from the company's board and shareholders, if necessary [4][5]. Impact on the Company - The changes in the special account and the re-signing of the supervision agreement are in line with regulatory requirements and are expected to enhance fund management without affecting the normal operation of investment projects [9][12]. - The board of directors and the audit committee have both approved the changes, confirming that they do not alter the intended use of the funds or the investment plans [10][11].

证券日报网讯 1月30日，金城医药发布公告称，控股股东金城实业将其所持13540000股公司股份质押展 期至2026年7月30日，占其持股17.24%，对应公司总股本3.53%，质权人为国泰海通证券股份有限公 司，不涉及新增融资。 （编辑 袁冠琳） ...

经济观察网证监会网站显示，深圳市华科精密工业股份有限公司2026年1月30日向深圳证监局办理辅导 备案登记，辅导机构为国泰海通证券股份有限公司。 ...

Core Viewpoint - Rujing Technology (301525.SZ) is currently experiencing a decline in stock price, with a closing price of 86.24 yuan and a drop of 9.04%, indicating a state of underperformance since its IPO [1] Group 1: IPO Details - Rujing Technology was listed on the Shenzhen Stock Exchange's ChiNext board on August 30, 2023, with an initial public offering (IPO) of 23,590,000 shares at a price of 99.57 yuan per share [1] - On its first trading day, Rujing Technology reached a peak price of 144.00 yuan, marking the highest price since its listing [2] - The total funds raised from the IPO amounted to 234,885.63 million yuan, with a net amount of 214,816.95 million yuan after deducting issuance costs, exceeding the initial plan by 116,629.75 million yuan [2] Group 2: Fund Utilization - The company intended to use the raised funds of 98,187.20 million yuan for projects related to the new energy vehicle electronics and smart manufacturing industrial base, as well as for the construction of a research and testing center and to supplement working capital [2] - The total issuance costs for the IPO were 20,068.68 million yuan, which included underwriting fees of 16,789.08 million yuan [2]